Business
/C O R R E C T I O N -- CytoSorbents Corporation/
In the news release, CytoSorbents to Host Key Opinion Leader Call on the Use of CytoSorb Blood Purification to Remove Antithrombotic Medications in Patients
About this update from Cytosorbents Corporation
[{"type":"text","content":"In the news release, CytoSorbents to Host Key Opinion Leader Call on the Use of CytoSorb Blood Purification to Remove Antithrombotic Medications in Patients at Risk of Bleeding, issued 29-Jun-2020 by CytoSorbents Corporation over PR Newswire, we are advised by the company that the conference call details and webcast information has changed. To reflect this, the third hyperlink in the first paragraph has been updated. Additionally, the \"Key Opinion Leader Call Details\" section after the third paragraph has been updated. The complete, corrected release follows:\n\nCytoSorbents to Host Key Opinion Leader Call on the Use of CytoSorb Blood Purification to Remove Antithrombotic Medications in Patients at Risk of Bleeding\n\n\nMONMOUTH JUNCTION, N.J., July 8, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announces that CytoSorbents will host a Key Opinion Leader call on the Use of CytoSorb to Remove Antithrombotic Medications in Patients at Risk of Bleeding, on Monday, July 13, 2020 at 11:00 AM EDT, featuring presentations by key experts:\n\n \n \n \n \n \n \n\n \nDr. C. Michael Gibson – Harvard University and Baim Institute for Clinical Research, USA Dr. Robert Storey – University of Sheffield, United Kingdom Prof. Dr. med. Michael Schmoeckel – Asklepios-Klinik St. Georg Hamburg, GermanyMillions of patients globally are taking antithrombotic medications, or \"blood thinners\", to reduce their risk of stroke and heart attacks. But when they require surgery, they risk life-threatening perioperative bleeding. The call will feature presentations from each of the distinguished speakers who will discuss the unmet medical need of managing patients on antithrombotic therapy requiring surgery. Drs. Gibson, Storey, and Schmoeckel will be available to answer questions at the conclusion of the event. \nThe discussion will be focused on the use of CytoSorb to remove two of the most commonly prescribed antithrombotic agents, ticagrelor (Brilinta®, Brilique®) and rivaroxaban (Xarelto®) from the bloodstream when installed in a heart-lung machine blood circuit during cardiothoracic surgery. CytoSorb has also received FDA Breakthrough Designation to remove t...